Please login to the form below
Astellas Pharma
This page shows the latest Astellas Pharma news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval
Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval. ... Astellas acquires UK gene therapy company Quethera. Japan’s Astellas Pharma is to acquire UK-based gene therapy company
Latest news
-
Daily Brief: Immunotherapy combos dominate ASCO, Pharma's Brexit warning, Big data and prostate cancer
Daily Brief: Immunotherapy combos dominate ASCO, Pharma's Brexit warning, Big data and prostate cancer. ... Alex Asiimwe, Director and Global TA head, epidemiology, Bayer. The consortium includes 32 companies, including most of the big pharma players in
-
J&J’s Erleada first US drug for non-metastatic prostate cancer
It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and Astellas and their Xtandi (enzalutamide) product, which has also been ... J&J acquired Erleada when it took over Aragon Pharma in 2013 in a deal valued at $1bn.
-
The power of pharma businesses to drive social change
In 2014, Astellas Pharma Europe provided a grant to the Fistula Foundation to develop Action on Fistula, our first corporate giving programme aimed at transforming the lives of more than 1, ... is corporate communications director of Astellas Pharma
-
FDA fast-tracks Astellas' Rydapt rival
FDA fast-tracks Astellas' Rydapt rival. AML treatment gilteritinib is currently involved in four phase III trials. ... Astellas Pharma has claimed a fast-track designation in the US for its FLT3 inhibitor gilteritinib, a drug that could rival
-
Astellas launches digital health investment company
Astellas launches digital health investment company. Will look for firms that focus on patient outcomes and offer pharma synergies. ... Digital inspiration for pharma on mobile, social media, strategy, best practice, regulations and more.
More from news
Approximately 1 fully matching, plus 100 partially matching documents found.
Latest Intelligence
-
The good, the bad and the ugly
AstraZeneca, Takeda, Astellas Pharma, Novo Nordisk and Recordati take up the final five positions, though only two - Takeda (3.9%) and Astellas (9.3%) - recorded growth. ... The data this article was based on is available in full online:
-
Case study: Action on Fistula
Client:Astellas Pharma EMEA Limited. Agency:Forster Communications. Campaign:Action on Fistula. Timescale:. A quick look. ... Action on Fistula, launched in May 2014, is an innovative partnership between Astellas Pharma EMEA Limited and the charity
-
Case study: Action on Fistula
Client:Astellas Pharma EMEA Limited. Agency:Forster Communications. Campaign:Action on Fistula. Timescale:. A quick look. ... Action on Fistula, launched in May 2014, is an innovative partnership between Astellas Pharma EMEA Limited and the charity
-
Japanese pharma pulls no punches with post-Brexit UK
Japanese pharma pulls no punches with post-Brexit UK. Firm want reassurance from the UK on its future in science and innovation. ... Yasuo Sakae, vice president of corporate strategy and planning at Astellas Pharma Europe, told PME that the company’s
-
Deal Watch July 2016
$225m. $36m. LEO Pharma. AstraZeneca. $1, 115m. $115m. Astellas. Cytokinetics. $100m. ... In at numbers 2, 3 and 4 are the LEO-AstraZeneca deal with an upfront of $115m, Astellas-Cytokinetics at $95m and Almirall-Sun Pharma at $50m (see below).
More from intelligence
Approximately 1 fully matching, plus 20 partially matching documents found.
Latest appointments
-
Astellas strengthens US and Canadian leadership team
Astellas has promoted Steve Sabus (pictured right) to general manager of Astellas Pharma Canada, effective from 1 April this year. ... needs.”. Sabus joined Astellas in 2007 and has over 25 years’experience in the pharmaceutical industry.
-
Dendreon appoints new R&D lead
Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
-
Stephen Eck joins Aravive Biologics
testing. Eck has served a number of global pharmaceutical companies in senior roles, including Eli Lilly and Pfizer, and most recently at Astellas Pharma as vice president of oncology medical sciences.
-
Astellas names Bob Chib to development leadership role
Astellas names Bob Chib to development leadership role. He takes up corporate strategy and planning position. ... Japanese pharma company Astellas has appointed Bob Chib to a leadership role within its US corporate development function.
-
MDxHealth creates new global commercial team
He brings over 30 years of pharmaceutical sales expertise to the roles, having held senior positions at Astellas Pharma, Lederle, Roussel Laboratoria and Yamanouchi.
More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest from PMHub
-
World’s Largest Pharmaceutical Summit Brings Latest Innovations To Light In New Award Ceremony
Astellas Pharma, Bayer, Pfizer and MSD are amongst the shortlisted companies who will join an exclusive celebration to recognise what really matters when it comes to supporting real patient outcomes. ... Customer Innovator Award and Lifetime Value
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
-
Associate Medical Director
-
Salary TBC
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
-
Account Director
-
Negotiable
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Scientific Team Lead
-
Competitive Salary
-
Associate Medical Director
-
Highly Competitive
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
-
Account Director - Digital
-
Great salary and benefits
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Experienced Editor, London, Medical Communications
-
Competitive package
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
- Director Healthcare PR Communications
-
Salary TBC
- Account Director – Global Healthcare PR
-
Salary TBC
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Scientific Director
-
Highly Competitive Salary &Benefits
- Account Manager, Healthcare Advertising
-
Salary TBC
Subscribe to our email news alerts
- Shire’s angioedema drug Takhzyro recommended in Europe
- Cuttsy+Cuttsy launch their latest patient e-book
- McCann Health London launch Urban Eye Test
- Encouraging data for GenSight’s blinding retinal disease gene therapy
- Keytruda hits survival targets in first-line kidney cancer
- UK ‘unicorn’ Oxford Nanopore bags $65m backing from Amgen
PMHub
Consulting at McCann Health
We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...
Latest intelligence
- Retaining reader value in plain language summaries of clinical studies
- Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
- Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
- Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
- Making Europe a leader in bioscience: boosting trust and opening minds
- A vision of Paris as Europe's leading hub for life sciences innovation...
Quick links
Infographics
